Peroxiredoxin 1 is a tumor-associated antigen in esophageal squamous cell carcinoma

Abstract

Peroxiredoxin 1 (Prdx1) is an antioxidant and plays an important role in H2O2-mediated cell signaling. We previously found that the expression level of Prdx1 was elevated in esophagus squamous cell carcinoma (ESCC) tissue using a proteomics approach. Since overexpressed protein can induce an autoimmune response, to further examine whether serum from ESCC patients exhibits immunoreactivity against Prdx1, autoantibody responses to Prdx1 were evaluated by ELISA, western blotting and indirect immunofluorescence assay in sera from patients with ESCC and normal individuals. Immunohistochemical study with tissue array slides and western blot analysis with cancer cell lines were also performed to analyze the protein expression profiles of Prdx1 in ESCC tissues and cancer cell lines. The results demonstrated that the positive rate of autoantibody against Prdx1 in ESCC sera was 13.2% (9/68), whereas this rate was 0% (0/89) in normal individuals. Data also showed that expression of Prdx1 was significantly increased in ESCC tissues when compared to expression in paired adjacent normal tissues (P<0.05). The data indicate that Prdx1 may contribute to malignant transformation of the esophagus, and may be used as a biomarker in the immunodiagnosis of ESCC.

Expression and clinical value of peroxiredoxin-1 in patients with pancreatic cancer

“…23,24 Ren et al 23 reported that Prx-1 as a tumor-associated antigen may conduce to malignant transformation in esophageal squamous cell carcinoma. Ha et al 24 revealed that Prx-1 excessive expression promotes epithelialemesenchymal transition (EMT) and cellular migration by inducing transforming growth factor beta1 (TGF-b1) in cancerous cells.…”

Alpha 2HS-glycoprotein, a tumor-associated antigen (TAA) detected in Mexican patients with early-stage breast cancer

“…However, these have been lacking in clinical usefulness because their sensitivity and specificity entertain values of < 70%, although many autoantigens may be detected by antibody-based methods and are considered candidates for oncogenic proteins [10,11,[20][21][22][23][24][25][26][29][30][31][32][33][34][35][38][39][40]. Validation of the most promising biomarkers proposed for the breast cancer diagnosis and prognosis has required the application of high evaluation standards in prospective cohort studies of women with breast cancer.…”

“…Using a proteomics approach has allowed the identification of autoantibodies against annexin-I, annexin-II [22], peroxiredoxin-I [23], calreticulin [24], and peroxiredoxin-VI [25], which have been found in the sera of patients with lung, pancreatic, and liver cancer. The presence of autoantibodies in serum against several tumor antigens, such as p53, embryonic neural proteins, and antineural/antinuclear antigens, has been also evaluated in breast cancer [26,27].…”

Peroxiredoxin 1 – an antioxidant enzyme in cancer

“…Proteomic study has found that the expression level of PRDX1 is elevated in oesophagus squamous cell carcinoma (ESCC) tissue 63. Further study demonstrated that PRDX1 is significantly increased in ESCC tissues compared with the paired adjacent normal tissues 15. In addition, several studies have identified that PRDX1 is overexpressed in ESCC cells compared with the non‐cancerous oesophageal epithelial cells 64, 65.…”

“…In addition to its peroxidase and chaperone functions, PRDX1 could also enhance natural killer cell cytotoxicity and suppress oncogenic proteins such as c‐Myc and c‐Abl 11, 12, 13. Recent studies have shown that abnormal expression of PRDX1 has been observed in several human cancers, including breast, oesophageal, lung and prostate cancers 14, 15, 16, 17. Furthermore, PRDX1 also regulates several ROS‐dependent signalling pathways and is thought to be a key intracellular intermediate balancing cell survival and apoptosis 7, 18.…”